Dear Research Advocate:
The cover story of this month’s National Geographic describes the recent wave of science doubt as a “pop culture meme,” featuring in-the-news examples like climate change and vaccines, and discussion of tough challenges like replicability of research, scientific literacy (of note: increased science literacy has been shown to lead to increased polarization of opinion about science), and what is meant, anyway, by effective “science communication”? The article doesn’t mention what I often call the “invisibility” problem (see, for example, data showing low percentages of Americans who can name a living scientist), but that topic was addressed directly and indirectly in several sessions at last week’s annual meeting of the American Association for the Advancement of Science (AAAS).
Data from a Pew Research poll of AAAS members show that a majority of scientists now believe that it is important to engage with the public, with a high percentage saying they do so regularly. That is welcome news. Another AAAS session brought out the importance of the quality of that engagement, exploring connecting with non-scientists in ways that is positive for both scientist and non-scientist. And, Professor Susan Fiske of Princeton spoke to an overflow crowd in her featured session about work showing that all of us – people in general – for better or worse, and with consequences to match – make quick judgments about others’ intent and their degree of competency. (Perception of competency + perception of good intent = trust.) Fiske noted that politicians are almost never trusted, although they are sometimes viewed as competent. Scientists are mostly considered competent, but they are also considered to be cold, a judgment that can throw their intentions into question. Fiske said that it is possible to change perceptions about scientists if they convey warmth and motivation to cooperate, showing ‘worthy intent.’ (If you have followed Research!America’s work in communicating to the non-science trained public, you know that we advocate saying and conveying, “I work for you.” That advice fits right in here.) Continue reading →
By Martine Rothblatt, PhD, Chairman and CEO of United Therapeutics Corporation.
Founded in 1996, United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have four approved products on the market today and we are not stopping there! From the United States to Europe to the Asia Pacific, we are proud of our multicultural business environment where employees can collaborate with people all over the world. As a group, we are relentless in our pursuit of “medicines for life”® and continue our research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.
We are proud to partner with Research!America to promote better medical advancements, biomedical research, and overall greater global health initiatives. We have seen first-hand how tireless research and dedication to a cause can change the lives of thousands of patients and their loved ones. We began our story by conducting extensive research on a treatment for a deadly disease so rare, Pulmonary Arterial Hypertension (PAH), that other medical companies had abandoned any pursuits for treatments or a cure. Continue reading →
Statement by Research!America President and CEO Mary Woolley on 21st Century Cures Initiative Discussion Draft
The release of the 21st Century Cures Initiative discussion draft is a major bipartisan accomplishment that represents a truly remarkable diversity of innovative ideas to speed the delivery of lifesaving treatments to patients – a testament to the extraordinary commitment of Congressman Fred Upton (R-MI), Congresswoman Diana DeGette (D-CO) and their respective staff members. The Initiative could be a game changer for the medical innovation ecosystem with provisions touching on virtually all phases of the research and development pipeline – from basic and applied research, to FDA review, to coverage and access. Among the many beneficial provisions Research!America fought for is a measure to reduce the administrative burden on researchers. We look forward to working with the 21st Century Cures team to greatly boost our nation’s commitment to groundbreaking research and drug development.
Public Health Thank You Day, November 24, 2014
ALEXANDRIA, Va.-November 20, 2014-As Thanksgiving approaches, Research!America and leading U.S. public health organizations urge Americans to salute public health professionals who go above and beyond to protect the health of our nation. Public Health Thank You Day honors all those unsung heroes who keep our drinking water safe and air clean, develop vaccines, track and investigate infections, and protect us against threats such as influenza, the Ebola and Enterovirus D68 outbreaks and natural disasters.
“Every day, public health professionals here and around the world work in challenging and sometimes dangerous situations to protect our health. The Ebola epidemic in West Africa and cases of Ebola in the U.S. are a reminder of the global nature of public health threats,” said Thomas R. Frieden, M.D., M.P.H., director of the Centers for Disease Control and Prevention (CDC). “Whether they are working to keep us safe from infectious disease threats, or finding ways to promote healthy opportunities, thanks to all the dedicated public health professionals who work to keep us safe and healthy.”
These everyday heroes include our health inspectors, environmental health scientists, laboratorians, epidemiologists, public health researchers, sanitation workers, nurses and many other dedicated workers. The CDC, local health departments and various institutions within our public health infrastructure have come together to address recent outbreaks, and public health professionals are tackling these threats head-on – as they do with other health challenges on a daily basis. Continue reading →
November 18, 2014
We extend warmest congratulations to Congressman Rush D. Holt, Ph.D., on the announcement of his new position as chief executive officer of The American Association for the Advancement of Science (AAAS) and executive publisher of Science family of journals. As a trained physicist, Representative Holt leveraged his scientific understanding to propel and enact policies that have contributed significantly to improving our nation’s health and economic security. During his distinguished tenure in Congress, he worked tirelessly to lift the ban on federal funding for embryonic stem cell research and helped enact the America COMPETES Act to strengthen investments in research and development. Representative Holt recognizes the value of inspiring the next generation of scientists, helping to restore investments in the Department of Education’s Mathematics and Science Partnerships program. His passion for science and commendable track record make him an exceptionally fine choice to lead one of the nation’s most highly-regarded and well-respected scientific organizations. We look forward to working closely with Representative Holt to build a deeper appreciation for science among policymakers and the general public. Outgoing AAAS CEO and Research!America board member, Alan Leshner, Ph.D., has been an outstanding leader and we are confident he will continue to be a prominent voice in science advocacy.
Statement by Research!America President and CEO Mary Woolley on Nobel Prize in Physiology or Medicine
Research!America congratulates this year’s Nobel Prize winners in physiology or medicine, Professor John O’Keefe of the University College London, and May-Britt and Edvard Moser, both of the Norwegian University of Science and Technology. Their discoveries of cells that provide the basis for how the brain maps surrounding space, allowing us to navigate complex environments, may lead to a better understanding of diseases such as Alzheimer’s, which afflicts 44 million people worldwide. O’Keefe, who as a postdoctoral fellow was supported by funding from the National Institutes of Health, made the first discovery of the brain’s “inner GPS” in 1971. The Mosers continued to develop his research, discovering another key component of the brain’s mapping system which shed more light on our ability to navigate. Continue reading →
Excerpt of a joint op-ed by Research!America President and CEO Mary Woolley and Susan G. Komen President and CEO Judith A. Salerno published in The Huffington Post.
February 23, 1954, was a milestone in the history of American medical research. That day, children at Arsenal Elementary School in Pittsburgh lined up to receive injections of a promising vaccine. Within months, schoolchildren all over the country were doing the same, and polio was on its way to being eradicated in the United States. The disease, which had killed and paralyzed children and adults alike, would no longer be a threat.
This remarkable achievement would not have been possible without the work of Dr. Jonas Salk and his team at the University of Pittsburgh, and — equally significant — grant support from the National Foundation for Infantile Paralysis, now known as March of Dimes. Policymakers played a role, too, when the Polio Vaccine Assistance Act of 1955 made possible federal grants to the states for purchase of the vaccine and for the costs of planning and conducting vaccination programs.
A generation or two later, millions of individuals worldwide benefited from another major medical breakthrough. Remember when being diagnosed as HIV-positive was an automatic death sentence in the 1980s? Accelerated research supported by the National Institutes of Health (NIH), in partnership with Burroughs Wellcome and Duke University, resulted in the development of AZT, the first drug that slowed the replication of HIV. By 1987, the drug won FDA approval and marked the first major treatment in extending the lives of HIV/AIDS patients. Continue reading →